2026 was a busy year on the state level. Whether it was the expected healthcare policy priorities or newer ones, there was plenty to […]
Mid-year review: State-level legislative action impacting biotech Read More »
On Tuesday July 28, the Arkansas State Board of Pharmacy suspended enforcement of a 2025 Arkansas law, Act 630, two months after a federal
Following court decision, Arkansas will not enforce Act 630 on drug distribution Read More »
Experts at the BIO International Convention examine the growth of the 340B drug pricing program, duplicate discounts, patient access, and calls for greater transparency.
BIO 2026: 340B faces growing calls for transparency, patient-focused reform Read More »
What will it take to build a stronger, more resilient U.S. life sciences industry? In a June 23 fireside chat at the 2026 BIO
BIO 2026: Gov. Tina Kotek on Oregon’s thriving bioscience sector Read More »
Patient advocates are praising Virginia Gov. Abigail Spanberger’s May 19 veto of Prescription Drug Affordability Board (PDAB) legislation (HB 483 and SB 271), arguing
Patient groups praise Virginia PDAB veto Read More »
“We’re finding that the most disruptive pieces of legislation are much more likely to advance in state legislatures first, before eventually gaining traction at
State of play: BIO Coffee Chat covers how state policies impact access Read More »
Known as “America’s Medicine Cabinet,” Puerto Rico is working to maintain its leadership in U.S. biotech production by becoming a hub for reshoring pharmaceutical
BIO on the American Road in Puerto Rico: ‘Medicine Cabinet’ ready to reshore Read More »
Historically, Charlotte has been recognized as a major U.S. financial hub. Now, the city is making significant strides in another transformative sector: health care
Charlotte emerging as a global leader in health care innovation and med tech Read More »
While U.S. biotech leadership is recognized as essential for national security, states also understand the industry’s local benefits and are implementing policies designed to
BIO-CSBA report explains why and how states seek to attract biotech Read More »
At a time when the biopharma industry is seeking to increase U.S. manufacturing, Indiana is in the vanguard—and still expanding. During a Nov. 11
BIO on the American Road: Indiana, a production powerhouse, is still expanding Read More »
